Pharmacokinetics of estradiol valerate 2mg + dienogest 2mg (Climodien® 2/2) after single and repeated oral administration in healthy postmenopausal women

Clinical Drug Investigation

Volumn 20, Issue 2, 2000, Pages 123-134

  Zimmerman, H ^a   Thebault, J J ^b   Duvauchelle, T ^b   Mignot, A ^b   Renoux, A ^b   Gualano, V ^b  

^a BAYER PHARMA AG   (Germany)

^b Aster Cephac   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DIENOGEST; DIENOGEST PLUS ESTRADIOL VALERATE; ESTRADIOL VALERATE; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG HALF LIFE; DRUG TOLERABILITY; FEMALE; HORMONE SUBSTITUTION; HUMAN; HUMAN EXPERIMENT; NORMAL HUMAN; POSTMENOPAUSE; PRIORITY JOURNAL; TESTOSTERONE BLOOD LEVEL;

EID: 0033857150     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200020020-00007     Document Type: Article

References (25)

1. Introduction: Structure-function relationships, metabolism, pharmacokinetics and potency of progestins
2. Organ targeting with the oral progestin dienogest
3. A 19-norprogestin without a 17α-ethinyl group I: Dienogest from a pharmacokinetic point of view
4. The menopause: Benefits and risks of estrogen-progestogen replacement therapy
5. Estrogen replacement therapy: A 10-year prospective study in relationship to osteoporosis
6. Guidance for clinical evaluation of combined estrogen/progestin-containing drug products used for hormone replacement therapy of postmenopausal women
7. Five years with continuous combined oestrogen/progestogen therapy. Effects on calcium metabolism, lipoproteins, and bleeding pattern
8. Clinical and metabolic responses of menopausal women to sequential versus continuous estrogen progestin replacement therapy
9. Effects of different progestogens on lipoproteins during post-menopausal replacement therapy
10. A long-term study of the effects of norethisterone on lipoprotein metabolism in menopausal women
11. Comparison of serum oestrogen concentrations in postmenopausal women taking estrone sulphate and estradiol
12. International harmonization of regulatory bioequivalence requirements
13. Pharmacokinetics of oral 17β-estradiol
14. Plasma concentration of medroxyprogesteroner acetate, estradiol and estrone following oral administration of Klimaxil®, Trisequence®/Provera® and Divina®. A randomized, single-blind, triple cross-over bioavailability study in menopausal women
15. Pharmacokinetic and pharmacodynamic studies on estradiol valerate administered orally to postmenopausal women
16. Bioequlvalence assessment of three different estradiol formulations in postmenopausal women in an open, randomized, single dose, 3 way cross-over study
17. Pharmacokinetics and biotransformation of estradiol valerate in ovarectomized women
18. Pharmacokinetics of percutaneous estradiol: A crossover study using a gel and a transdermal system in comparison with oral micronized estradiol
19. Pharmacokinetic evaluation of oral 17β-estradiol and two different fat soluble analogues in ovariectomized women
20. Single dose pharmacokinetics of sublingual versus oral administration of micronized 17β-estradiol
21. Pharmacokinetics of orally administered estradiol valerate. Results of a single dose cross-over bioequivalence study in postmenopausal women
22. Pharmacokinetics of estradiol and of estrone during repeated transdermal or oral administration of estradiol
23. Liver inclusive protein, lipid and carbohydrate metabolism